Biopharmaceutical Contract Manufacturing Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Biopharmaceutical Contract Manufacturing Market Size Analysis

Global Biopharmaceutical Contract Manufacturing Market Introduction
By Service
1. Introduction
  1. Service By Value
2. Process Development
  1. By Value
  2. Upstream
    1. Upstream By Value
  3. Downstream
    1. Downstream By Value
3. Analytical & QC studies
  1. By Value
4. Fill & Finish Operations
  1. By Value
5. Packaging & Labelling
  1. By Value
6. Others
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Mammalian
  1. By Value
3. Non-mammalian
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
  2. Monoclonal antibodies
    1. Monoclonal antibodies By Value
  3. Recombinant Proteins
    1. Recombinant Proteins By Value
  4. Vaccines
    1. Vaccines By Value
  5. Cell and Gene Therapy
    1. Cell and Gene Therapy By Value
  6. Therapeutic Peptides & Proteins
    1. Therapeutic Peptides & Proteins By Value
    2. Others
      1. Others By Value
3. Biosimilars
  1. By Value
By Product Type
1. Introduction
  1. Product Type By Value
2. Drug Substance
  1. By Value
3. Finished Drug Product
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Infectious Diseases
  1. By Value
5. Cardiovascular Diseases
  1. By Value
6. Metabolic Diseases
  1. By Value
7. Neurology
  1. By Value
8. Others
  1. By Value

North America Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Process Development
  1. By Value
  2. Upstream
    1. Upstream By Value
  3. Downstream
    1. Downstream By Value
3. Analytical & QC studies
  1. By Value
4. Fill & Finish Operations
  1. By Value
5. Packaging & Labelling
  1. By Value
6. Others
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Mammalian
  1. By Value
3. Non-mammalian
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
  2. Monoclonal antibodies
    1. Monoclonal antibodies By Value
  3. Recombinant Proteins
    1. Recombinant Proteins By Value
  4. Vaccines
    1. Vaccines By Value
  5. Cell and Gene Therapy
    1. Cell and Gene Therapy By Value
  6. Therapeutic Peptides & Proteins
    1. Therapeutic Peptides & Proteins By Value
    2. Others
      1. Others By Value
3. Biosimilars
  1. By Value
By Product Type
1. Introduction
  1. Product Type By Value
2. Drug Substance
  1. By Value
3. Finished Drug Product
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Infectious Diseases
  1. By Value
5. Cardiovascular Diseases
  1. By Value
6. Metabolic Diseases
  1. By Value
7. Neurology
  1. By Value
8. Others
  1. By Value
U.S.
1. By Service
  1. Introduction
    1. Service By Value
  2. Process Development
    1. By Value
    2. Upstream
      1. Upstream By Value
    3. Downstream
      1. Downstream By Value
  3. Analytical & QC studies
    1. By Value
  4. Fill & Finish Operations
    1. By Value
  5. Packaging & Labelling
    1. By Value
  6. Others
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Mammalian
    1. By Value
  3. Non-mammalian
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
    2. Monoclonal antibodies
      1. Monoclonal antibodies By Value
    3. Recombinant Proteins
      1. Recombinant Proteins By Value
    4. Vaccines
      1. Vaccines By Value
    5. Cell and Gene Therapy
      1. Cell and Gene Therapy By Value
    6. Therapeutic Peptides & Proteins
      1. Therapeutic Peptides & Proteins By Value
      2. Others
        
        Others By Value
  3. Biosimilars
    1. By Value
4. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Drug Substance
    1. By Value
  3. Finished Drug Product
    1. By Value
5. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Cardiovascular Diseases
    1. By Value
  6. Metabolic Diseases
    1. By Value
  7. Neurology
    1. By Value
  8. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Process Development
  1. By Value
  2. Upstream
    1. Upstream By Value
  3. Downstream
    1. Downstream By Value
3. Analytical & QC studies
  1. By Value
4. Fill & Finish Operations
  1. By Value
5. Packaging & Labelling
  1. By Value
6. Others
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Mammalian
  1. By Value
3. Non-mammalian
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
  2. Monoclonal antibodies
    1. Monoclonal antibodies By Value
  3. Recombinant Proteins
    1. Recombinant Proteins By Value
  4. Vaccines
    1. Vaccines By Value
  5. Cell and Gene Therapy
    1. Cell and Gene Therapy By Value
  6. Therapeutic Peptides & Proteins
    1. Therapeutic Peptides & Proteins By Value
    2. Others
      1. Others By Value
3. Biosimilars
  1. By Value
By Product Type
1. Introduction
  1. Product Type By Value
2. Drug Substance
  1. By Value
3. Finished Drug Product
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Infectious Diseases
  1. By Value
5. Cardiovascular Diseases
  1. By Value
6. Metabolic Diseases
  1. By Value
7. Neurology
  1. By Value
8. Others
  1. By Value
U.K.
1. By Service
  1. Introduction
    1. Service By Value
  2. Process Development
    1. By Value
    2. Upstream
      1. Upstream By Value
    3. Downstream
      1. Downstream By Value
  3. Analytical & QC studies
    1. By Value
  4. Fill & Finish Operations
    1. By Value
  5. Packaging & Labelling
    1. By Value
  6. Others
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Mammalian
    1. By Value
  3. Non-mammalian
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
    2. Monoclonal antibodies
      1. Monoclonal antibodies By Value
    3. Recombinant Proteins
      1. Recombinant Proteins By Value
    4. Vaccines
      1. Vaccines By Value
    5. Cell and Gene Therapy
      1. Cell and Gene Therapy By Value
    6. Therapeutic Peptides & Proteins
      1. Therapeutic Peptides & Proteins By Value
      2. Others
        
        Others By Value
  3. Biosimilars
    1. By Value
4. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Drug Substance
    1. By Value
  3. Finished Drug Product
    1. By Value
5. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Cardiovascular Diseases
    1. By Value
  6. Metabolic Diseases
    1. By Value
  7. Neurology
    1. By Value
  8. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Process Development
  1. By Value
  2. Upstream
    1. Upstream By Value
  3. Downstream
    1. Downstream By Value
3. Analytical & QC studies
  1. By Value
4. Fill & Finish Operations
  1. By Value
5. Packaging & Labelling
  1. By Value
6. Others
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Mammalian
  1. By Value
3. Non-mammalian
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
  2. Monoclonal antibodies
    1. Monoclonal antibodies By Value
  3. Recombinant Proteins
    1. Recombinant Proteins By Value
  4. Vaccines
    1. Vaccines By Value
  5. Cell and Gene Therapy
    1. Cell and Gene Therapy By Value
  6. Therapeutic Peptides & Proteins
    1. Therapeutic Peptides & Proteins By Value
    2. Others
      1. Others By Value
3. Biosimilars
  1. By Value
By Product Type
1. Introduction
  1. Product Type By Value
2. Drug Substance
  1. By Value
3. Finished Drug Product
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Infectious Diseases
  1. By Value
5. Cardiovascular Diseases
  1. By Value
6. Metabolic Diseases
  1. By Value
7. Neurology
  1. By Value
8. Others
  1. By Value
China
1. By Service
  1. Introduction
    1. Service By Value
  2. Process Development
    1. By Value
    2. Upstream
      1. Upstream By Value
    3. Downstream
      1. Downstream By Value
  3. Analytical & QC studies
    1. By Value
  4. Fill & Finish Operations
    1. By Value
  5. Packaging & Labelling
    1. By Value
  6. Others
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Mammalian
    1. By Value
  3. Non-mammalian
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
    2. Monoclonal antibodies
      1. Monoclonal antibodies By Value
    3. Recombinant Proteins
      1. Recombinant Proteins By Value
    4. Vaccines
      1. Vaccines By Value
    5. Cell and Gene Therapy
      1. Cell and Gene Therapy By Value
    6. Therapeutic Peptides & Proteins
      1. Therapeutic Peptides & Proteins By Value
      2. Others
        
        Others By Value
  3. Biosimilars
    1. By Value
4. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Drug Substance
    1. By Value
  3. Finished Drug Product
    1. By Value
5. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Cardiovascular Diseases
    1. By Value
  6. Metabolic Diseases
    1. By Value
  7. Neurology
    1. By Value
  8. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Process Development
  1. By Value
  2. Upstream
    1. Upstream By Value
  3. Downstream
    1. Downstream By Value
3. Analytical & QC studies
  1. By Value
4. Fill & Finish Operations
  1. By Value
5. Packaging & Labelling
  1. By Value
6. Others
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Mammalian
  1. By Value
3. Non-mammalian
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
  2. Monoclonal antibodies
    1. Monoclonal antibodies By Value
  3. Recombinant Proteins
    1. Recombinant Proteins By Value
  4. Vaccines
    1. Vaccines By Value
  5. Cell and Gene Therapy
    1. Cell and Gene Therapy By Value
  6. Therapeutic Peptides & Proteins
    1. Therapeutic Peptides & Proteins By Value
    2. Others
      1. Others By Value
3. Biosimilars
  1. By Value
By Product Type
1. Introduction
  1. Product Type By Value
2. Drug Substance
  1. By Value
3. Finished Drug Product
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Infectious Diseases
  1. By Value
5. Cardiovascular Diseases
  1. By Value
6. Metabolic Diseases
  1. By Value
7. Neurology
  1. By Value
8. Others
  1. By Value
UAE
1. By Service
  1. Introduction
    1. Service By Value
  2. Process Development
    1. By Value
    2. Upstream
      1. Upstream By Value
    3. Downstream
      1. Downstream By Value
  3. Analytical & QC studies
    1. By Value
  4. Fill & Finish Operations
    1. By Value
  5. Packaging & Labelling
    1. By Value
  6. Others
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Mammalian
    1. By Value
  3. Non-mammalian
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
    2. Monoclonal antibodies
      1. Monoclonal antibodies By Value
    3. Recombinant Proteins
      1. Recombinant Proteins By Value
    4. Vaccines
      1. Vaccines By Value
    5. Cell and Gene Therapy
      1. Cell and Gene Therapy By Value
    6. Therapeutic Peptides & Proteins
      1. Therapeutic Peptides & Proteins By Value
      2. Others
        
        Others By Value
  3. Biosimilars
    1. By Value
4. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Drug Substance
    1. By Value
  3. Finished Drug Product
    1. By Value
5. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Cardiovascular Diseases
    1. By Value
  6. Metabolic Diseases
    1. By Value
  7. Neurology
    1. By Value
  8. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Service
1. Introduction
  1. Service By Value
2. Process Development
  1. By Value
  2. Upstream
    1. Upstream By Value
  3. Downstream
    1. Downstream By Value
3. Analytical & QC studies
  1. By Value
4. Fill & Finish Operations
  1. By Value
5. Packaging & Labelling
  1. By Value
6. Others
  1. By Value
By Source
1. Introduction
  1. Source By Value
2. Mammalian
  1. By Value
3. Non-mammalian
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Biologics
  1. By Value
  2. Monoclonal antibodies
    1. Monoclonal antibodies By Value
  3. Recombinant Proteins
    1. Recombinant Proteins By Value
  4. Vaccines
    1. Vaccines By Value
  5. Cell and Gene Therapy
    1. Cell and Gene Therapy By Value
  6. Therapeutic Peptides & Proteins
    1. Therapeutic Peptides & Proteins By Value
    2. Others
      1. Others By Value
3. Biosimilars
  1. By Value
By Product Type
1. Introduction
  1. Product Type By Value
2. Drug Substance
  1. By Value
3. Finished Drug Product
  1. By Value
By Therapeutic Area
1. Introduction
  1. Therapeutic Area By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Infectious Diseases
  1. By Value
5. Cardiovascular Diseases
  1. By Value
6. Metabolic Diseases
  1. By Value
7. Neurology
  1. By Value
8. Others
  1. By Value
Brazil
1. By Service
  1. Introduction
    1. Service By Value
  2. Process Development
    1. By Value
    2. Upstream
      1. Upstream By Value
    3. Downstream
      1. Downstream By Value
  3. Analytical & QC studies
    1. By Value
  4. Fill & Finish Operations
    1. By Value
  5. Packaging & Labelling
    1. By Value
  6. Others
    1. By Value
2. By Source
  1. Introduction
    1. Source By Value
  2. Mammalian
    1. By Value
  3. Non-mammalian
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Biologics
    1. By Value
    2. Monoclonal antibodies
      1. Monoclonal antibodies By Value
    3. Recombinant Proteins
      1. Recombinant Proteins By Value
    4. Vaccines
      1. Vaccines By Value
    5. Cell and Gene Therapy
      1. Cell and Gene Therapy By Value
    6. Therapeutic Peptides & Proteins
      1. Therapeutic Peptides & Proteins By Value
      2. Others
        
        Others By Value
  3. Biosimilars
    1. By Value
4. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Drug Substance
    1. By Value
  3. Finished Drug Product
    1. By Value
5. By Therapeutic Area
  1. Introduction
    1. Therapeutic Area By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Cardiovascular Diseases
    1. By Value
  6. Metabolic Diseases
    1. By Value
  7. Neurology
    1. By Value
  8. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Biopharmaceutical Contract Manufacturing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

AGC Biologics
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Biocon Limited
Boehringer Ingelheim International GmbH
Catalent, Inc.
Charles River Laboratories International, Inc.
FUJIFILM Diosynth Biotechnologies
GenScript Biotech Corporation
KBI Biopharma, Inc.
Lonza Group Ltd.
Merck KGaA
Pfizer Inc.
Horiba Ltd.
Rentschler Biopharma SE
Stelis Biopharma
Thermo Fisher Scientific Inc.
Rakuten Medical, Inc.
WuXi Biologics
Fresenius SE & Co. KGaA

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment